Designation
Consultant Gastrohepatologist
Institution
Hospital Queen Elizabeth 1,
Sabah
Qualification
MBBS,MRCP(UK) , Fellowship in Advance Hepatology(OXF)
Special field of interest
Cholestatic and Autoimmune Liver Diseases , Portal Hypertension .
Abstract
| Title: |
Hepatitis Screening and Treatment Pre-Transplantation |
| Body: |
Hepatitis screening and treatment prior to transplantation are critical components in the management of patients with liver disease, aiming to optimize transplant outcomes and reduce post-operative complications. The process involves comprehensive screening for hepatitis B virus (HBV), hepatitis C virus (HCV), and other hepatitis pathogens to identify active infections and assess disease severity. Advances in antiviral therapies, including direct-acting antivirals (DAAs) for HCV and nucleos(t)ide analogs for HBV, have significantly improved the ability to control viral replication before transplantation. Achieving viral suppression or clearance is associated with decreased risk of reinfection and improved graft survival. Moreover, pre-transplant hepatitis management requires careful consideration of timing, potential drug interactions, and the patient's overall health status. Integration of hepatitis screening and treatment protocols into the transplant evaluation process enhances patient outcomes by reducing infectious risks, delaying disease progression, and increasing the likelihood of successful transplantation. Continued research and development of novel antiviral agents and strategies are essential to further improve pre-transplant hepatitis management and ultimately, long-term transplant success |
